Intercept Pharmaceuticals, the developer of liver disease drug Ocaliva, has agreed to be acquired by Italian Pharma company Alfasigma in an all-cash deal worth approximately $800 million. Intercept ...
Shares of Intercept Pharmaceuticals, Inc. ICPT gained 12.4% in the last six months compared with the industry’s growth of 0.3%. Investors are upbeat on the performance of lead drug Ocaliva and the ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood ...
SAN JOSE, Calif.--(BUSINESS WIRE)--DTEX Systems, the global leader for insider risk management, today announced the availability of DTEX InTERCEPT™ on Google Cloud Marketplace, expanding global access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results